During the past decade, Temple University Cancer Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Temple University Cancer Center" #1 sponsor was "Temple University" with 3 trials, followed by "INSYS Therapeutics Inc" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Therion Biologics Corporation" with 1 trials sponsored and "UNC Lineberger Comprehensive Cancer Center" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Temple University Cancer Center" #1 collaborator was "Fox Chase Cancer Center" with 3 trials as a collaborator, "Georgetown University" with 2 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Temple University Cancer Center" are "Breast Cancer" (2 trials), "Neoplasms" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Extragonadal Germ Cell Tumor" (1 trials) and "Lymphoma" (1 trials). Many other conditions were trialed in "Temple University Cancer Center" in a lesser frequency.

Most popular intervention types in "Temple University Cancer Center" are "Drug" (7 trials), "Biological" (4 trials), "Procedure" (4 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "peripheral blood stem cell transplantation" (4 trials), "carboplatin" (3 trials), "cyclophosphamide" (3 trials), "etoposide" (3 trials) and "filgrastim" (3 trials). Other intervention names were less common.

The vast majority of trials in "Temple University Cancer Center" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Temple University Cancer Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Temple University Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Temple University Cancer Center, 5 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".